Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics. CA Cancer J Clin 2006;56:106-30
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-61
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. Hematol J 1997;1:53-66
   Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-43
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology 2011;243-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13
   PubMed Web of Science ®Google Scholar
• Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005;88:1-50
   PubMed Web of Science ®Google Scholar
• Raponi S, Stefania de Propris M, Intoppa S, Flow cytometry study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-107
   PubMed Web of Science ®Google Scholar
• Gudowius S, Recker K, Laws HJ, Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Pediatr 2006;218:327-33
   PubMed Web of Science ®Google Scholar
• Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 1995;154:4466-75
   PubMed Web of Science ®Google Scholar
• Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lumphocyte antigen receptor. Semin Immunol 1998;10:287-97
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51
   PubMed Web of Science ®Google Scholar
• Linden O, Hindorf C, Cavallin-Stahl E, Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11:5215-22
   PubMed Web of Science ®Google Scholar
• Dubowchik G, Walker M. Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs. Pharmacol Ther 1999;83:67-123
   PubMed Web of Science ®Google Scholar
• Thorson J, Sievers E, Ahlert J, Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-79
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha AM, McGahren WJ, Ellestag GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201
   PubMed Web of Science ®Google Scholar
• Walker S, Landovitz R, Ding WD, Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci USA 1992;89:4608-12
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Armellino DC, Bogaert ER, Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004;103:1807-14
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Kalyandrug LB, Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242-9
   PubMed Web of Science ®Google Scholar
• Damle NK. Tumor-targeted chemotherapy using immunoconjugates of calicheamicin. Expert Opin Biol Ther 2004;4:1445-52
   PubMed Web of Science ®Google Scholar
• Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 2003;3:386-90
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Evans DY, Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted chemotherapy CVP or CHOP. Cancer Chemother Pharmacol 2011;67:741-9
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Armellino DC, Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240-5
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Jurgens H, Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003;17:468-70
   PubMed Web of Science ®Google Scholar
• De Vries JF, Zwaan CM, De Bie M, The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• DiJoseph JF, Goad ME, Dougher MM, Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Yamakage N, CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009;146:34-43
   PubMed Web of Science ®Google Scholar
• Takeshita A, Yamakage N, Shinjo K, CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 2009;23:1329-36
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Kalyandrug L, Damle NK. Anti-tumor activity of CMC-544 in combination with rituximab [abstract #700]. Proc Am Assoc Cancer Res 2005;46:165
   Google Scholar
• Macor P, Tripodo C, Zorzet S, In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63
   PubMed Web of Science ®Google Scholar
• Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251-8
   PubMed Web of Science ®Google Scholar
• Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27
   PubMed Web of Science ®Google Scholar
• Fayad L, Patel H, Verhoef G, Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study [abstract #2711]. Blood 2006;108:766a
   Web of Science ®Google Scholar
• Johnson P, Fayad L, Coiffier B, Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in recurrent/refractory follicular lymphoma or diffuse large B-cell lymphoma [abstract #407]. Haematologica 2009;94:165
   Web of Science ®Google Scholar
• Dang NH, Smith MR, Offner F, Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or ‘aggressive' lymphoma [abstract #584]. Blood 2009;114:242
   Web of Science ®Google Scholar
• Advani A, Coiffier B, Czuczman MS, Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93
   PubMed Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010;101:1840-5
   PubMed Web of Science ®Google Scholar
• Lobo E, Hansen R, Balthasar J. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68
   PubMed Web of Science ®Google Scholar
• Mager D, Jusko W. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28:507-32
   PubMed Web of Science ®Google Scholar
• Brambell F, Hemmings W, Morris I. A theoretical model of gamma-globulin catabolism. Nature 1969;203:1352-4
   Google Scholar
• Ogura M, Hatake K, Ando K, Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Kebriaei P, Wilhelm K, Ravandi F, Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Blood 2011;118(suppl. 1)[abstract #3102]
   Google Scholar
• Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163-205
   PubMed Web of Science ®Google Scholar
• Tavernier E, Boiron JM, Huguet F, Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-14
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian H, Smith TL, Primary refractory and relapsed acute lymphoblastic leukaemia. Cancer 1999;86:1216-30
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandes-Rivas JM, Outcome after relapse of acute lymphoblastic leukaemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-96
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH, CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab. Blood 2007;109:4168-70
   PubMed Web of Science ®Google Scholar
• Thomas D, Faderl S, O'Brien S, Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-80
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Rituximab in the treatment of adult ALL. Ann Hematol 2006;85:117-19
   Web of Science ®Google Scholar
• Thomas D, O'Brien S, Faderl S, Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-9
   PubMed Web of Science ®Google Scholar
• Thomas X, Olteanu N, Charrin C, Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 2001;67:73-83
   PubMed Web of Science ®Google Scholar
• Robak T, Szmigielska-Kaplon A, Wrzesien-Kus A, Acute lymphoblastic leukemia in elderly: the polish adult leukemia group experience. Ann Hematol 2004;83:225-31
   PubMed Web of Science ®Google Scholar
• Pagano L, Mele L, Casorelli I, Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 2000;85:1327-9
   PubMed Web of Science ®Google Scholar